NEW YORK (GenomeWeb News) – Jivan Biologics said yesterday that the US Patent and Trademark Office will re-examine a patent held by Paris-based ExonHit Therapeutics covering methods for identifying differentially spliced gene products.
 
The patent, No. 6,881,571, is at the center of a patent infringement suit filed last year by ExonHit against Larkspur, Calif.-based Jivan.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.